Distinguished in Bone Tumor

Dr. Siqing Y. Fu

Hematology Oncology | Hematology | Oncology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Bone Tumor
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Siqing Fu is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Fu is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Lung Cancer, Alveolar Soft Part Sarcoma, and Colorectal Cancer.

His clinical research consists of co-authoring 242 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Bone Tumor.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer
A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer
Enrollment Status: Recruiting
Publish Date: May 15, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Other, Drug, Procedure
Study Drugs: Cediranib Maleate, Olaparib
Study Phase: Phase 2
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of Cabozantinib and Pamiparib to Evaluate Triple Inhibition of PARP, VEGFR and c-MET in Advanced Homologous Recombination Deficient Malignancies
A Phase I Study of Cabozantinib and Pamiparib to Evaluate Triple Inhibition of PARP, VEGFR and c-MET in Advanced Homologous Recombination Deficient Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 1
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drugs: LVGN3616+LVGN6051+Nab-Paclitaxel, LVGN3616+LVGN6051+Bevacizumab+Cyclophosphamide, LVGN3616+LVGN6051+LVGN7409+Nab-Paclitaxel, LVGN3616+LVGN6051+LVGN7409+Bevacizumab+Cyclophosphamide
Study Phase: Phase 1
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: CAB-ROR2-ADC
Study Phase: Phase 1/Phase 2
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: Pamiparib, Temozolomide
Study Phase: Phase 1
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
Enrollment Status: Terminated
Publish Date: December 13, 2024
Intervention Type: Drug, Other
Study Drug: NIR178
Study Phase: Phase 1
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Biological, Other
Study Drugs: Galinpepimut-S, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: SOR-C13 TRPV6 Calcium Channel Inhibitor
Study Phase: Phase 1
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Enrollment Status: Withdrawn
Publish Date: June 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors
A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 28, 2023
Intervention Type: Drug, Other
Study Drugs: Paclitaxel, TAK-659 Spleen Tyrosine Kinase Inhibitor
Study Phase: Phase 1
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug
Study Phase: Phase 2
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2022
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Pembrolizumab
Study Phase: Phase 2
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors
A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors
Enrollment Status: Suspended
Publish Date: May 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: September 03, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 07, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 26 Less Clinical Trials

242 Total Publications

Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.
Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.
Journal: ESMO open
Published: February 28, 2025
Similar Doctors
Distinguished in Bone Tumor
Dr. Ravin Ratan
Hematology Oncology | Oncology | Hematology
Distinguished in Bone Tumor
Dr. Ravin Ratan
Hematology Oncology | Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravin Ratan is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Ratan is rated as an Elite provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, Gamma Knife Radiosurgery, and Bone Marrow Aspiration.

Elite in Bone Tumor
Dr. Shreyaskumar Patel
Oncology
Elite in Bone Tumor
Dr. Shreyaskumar Patel
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shreyaskumar Patel is an Oncologist in Houston, Texas. Dr. Patel is rated as an Elite provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, Osteotomy, and Pancreaticoduodenectomy.

Distinguished in Bone Tumor
Dr. Anthony Conley
Oncology
Distinguished in Bone Tumor
Dr. Anthony Conley
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Conley is an Oncologist in Houston, Texas. Dr. Conley is rated as an Elite provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Chondrosarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fu's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 74 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile